SIMPLE AntibodyTM platform generates unique species cross-reactive antibodies against immune checkpoints

$

Antibody Engineering & Therapeutics Conference

15 December 2017

Erik Hofman, Senior Scientist

Forward Looking Statements

THIS PRESENTATION HAS BEEN PREPARED BY ARGENX SE (“ARGENX” OR THE “COMPANY”) FOR INFORMATIONAL PURPOSES ONLY AND NOT FOR ANY OTHER PURPOSE. NOTHING CONTAINED IN THIS PRESENTATION IS, OR SHOULD BE CONSTRUED AS, A RECOMMENDATION, PROMISE OR REPRESENTATION BY THE PRESENTER OR THE COMPANY OR ANY DIRECTOR, EMPLOYEE, AGENT, OR ADVISER OF THE COMPANY. THIS PRESENTATION DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN ALL OF THE INFORMATION YOU MAY DESIRE. THIS PRESENTATION ALSO CONTAINS ESTIMATES AND OTHER STATISTICAL DATA MADE BY INDEPENDENT PARTIES AND BY US RELATING TO MARKET SIZE AND GROWTH AND OTHER DATA ABOUT OUR INDUSTRY. THIS DATA INVOLVES A NUMBER OF ASSUMPTIONS AND LIMITATIONS, AND YOU ARE CAUTIONED NOT TO GIVE UNDUE WEIGHT TO SUCH ESTIMATES.

Safe Harbor: Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding our investigational product candidates and preclinical and clinical trials and the status and related results thereto, future results of operations and financial positions, business strategy, plans and our objectives for future operations. When used in this presentation, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “will,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions identify forward-looking statements. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Such risks include, but are not limited to: the impact of general economic conditions, general conditions in the biopharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which the Company does or plans to do business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current analysis and expectations include:

failure to demonstrate the safety, tolerability and efficacy of our product candidates; final and quality controlled verification of data and the related analyses; the expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to conduct additional clinical trials and our reliance on third parties such as our licensors and collaboration partners regarding our suite of technologies and product candidates. Further, even if regulatory approval is obtained, biopharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including in the final prospectus related to the Company’s initial U.S. public offering filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended, as well as subsequent filings and reports filed by the Company with the SEC. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

• Company overview

• SIMPLE antibodyTM platform

• PD-1

• VISTA

• LAG-3

• Innovative access program

Agenda

Validating selective partnerships

Powerful technology suite

Novel concept in autoimmunity

• ARGX-110: first-in-class CD70 antagonist in Phase 1/2 in CTCL and AML

• 4 clinical stage programs; 3 preclinical programs; Innovative Access Program

Deep pipeline with multiple shots on goal

• ARGX-113: first-in-class FcRn antagonist targeting array of IgG mediated AI diseases

• Phase 1: favorable safety profile; IgG reduction up to 85%

• Phase 2: ongoing in myasthenia gravis, immune thrombocytopenia and pemphigus vulgaris

• Strong cash position: €162mm Sept 30, 2017

• Blue chip investor base: more than 50% U.S. Shareholders

• 26.9 mio shares outstanding

• SIMPLE Antibody™: Human V-regions sourced from llama unlock novel & complex targets

• NHance®, ABDEG™, POTELLIGENT®: Fc engineering to augment natural properties of antibodies

• : ARGX-115 (Immuno-oncology-focused novel target GARP)

• $40mm upfront and up to $625mm in potential milestone payments

• Additional partnerships designed to maximize value of platform in non-core areas

Company HighlightsDifferentiated therapeutic antibodies pioneering in severe autoimmune diseases & cancer

Well financed to execute plan

$

4

Discovery

Disciplined Business ModelMaximizes value of our suite of technologies and capabilities

Differentiated mAbsNovel Targetsargenx

Technology Suite

Generating differentiated antibody candidates...

...capturing value at optimal stages

Platform dealsProduct deals

large indications

ARGX-109

ARGX-112

ARGX-116

Bird Rock Bio✓

✓

✓

✓

✓

ARGX-113

ARGX-110

ARGX-115

ARGX-111

✓

Product dealsoutside strategic focus

Product portfolioprogress to clinical PoC

Value inflection point

5

Preclinical development Early & late clinical development

✓

• We obtained the exclusive license option from Broteio Pharma for an antibody against a novel complement target

• We have an antibody discovery alliance with focused on multiple rare disease targets

Deep Pipeline In Severe Autoimmune Diseases and Cancer

6

Product Candidate

Target Indication Preclinical Phase 1 Phase 2 Phase 3 Next Milestone / Commentary

Wholly-Owned Product Candidates

ARGX-113(efgartigimod)

FcRn

Myasthenia Gravis

Immune Thrombocytopenia

Pemphigus Vulgaris

Chronic Autoimmune Diseases

1Q18: Phase 2 topline results

2H18: Phase 2 topline results

2H18: Phase 2 interim data

2H17: Initiate Phase 1 clinical trial

ARGX-110(cusatuzumab)

CD70T-Cell Lymphoma

Acute Myeloid Leukemia

2H18: Phase 2 topline results CTCL

YE17: Interim update Phase 2 CTCL and Phase 1 dose-escalation in AML/MDS

ARGX-111 c-MET Solid Tumors / Blood Cancer Intend to partner

Partnered Product Candidates

ARGX-109(gerilimzumab)

IL-6 Rheumatoid ArthritisEligible for up to €32.5mm in milestones, royalties & additional shares of Bird Rock stock

ARGX-112 IL-22R Skin InflammationEligible for up to ~€100mm in milestones and tiered royalties

ARGX-115 GARP Cancer ImmunotherapyReceived $50mm so far; eligible for up to $625mm milestones & tiered royalties

ARGX-116 ApoC3 DyslipidemiaEligible for double-digit royalties and exclusive option to license the program

Phase 1/2

Phase 1/2

SubQ Formulation

Agenda

• Company overview

• SIMPLE antibodyTM platform

• PD-1

• VISTA

• LAG-3

• Innovative access program

Augmenting Intrinsic Therapeutic Properties Of Antibodies

8

• Llama immune system delivers V-regions with high human homology

V-region

Fc region

SIMPLE Antibody™ Platform

Suite of technologiesTechnology RoleAntibody

Unlock novel and complex targets

We apply our unique suite of technologies to create differentiated product candidates against novel targets

Klarenbeek et al. 2015, mAbsBasilico et al. 2014, J Clin Inv.

Augmenting Intrinsic Therapeutic Properties Of Antibodies

9

• Llama immune system delivers V-regions with high human homology

• Low sequence identity to target protein gives solid immune responses after immunization

• Highly diverse antibody output covers a multitude of target epitopes

V-region

Fc region

SIMPLE Antibody™ Platform

Suite of technologiesTechnology RoleAntibody

Unlock novel and complex targets

We apply our unique suite of technologies to create differentiated product candidates against novel targets

Klarenbeek et al. 2015, mAbsBasilico et al. 2014, J Clin Inv.

Augmenting Intrinsic Therapeutic Properties Of Antibodies

10

• Extends half-life

• Enhances tissue penetration

• Clears disease target

• Clears autoantibodies

• Boosts cell killing

• Llama immune system delivers V-regions with high human homology

• Low sequence identity to target protein gives solid immune responses after immunization

• Highly diverse antibody output covers a multitude of target epitopes

V-region

Fc region

SIMPLE Antibody™ Platform

Suite of technologiesTechnology Role

NHance®

ABDEG™

POTELLIGENT®

Antibody

Unlock novel and complex targets

Modulate immune response

We apply our unique suite of technologies to create differentiated product candidates against novel targets

Klarenbeek et al. 2015, mAbsBasilico et al. 2014, J Clin Inv.

SIMPLE AntibodyTM platform: powerful engine behind argenx’ pipeline

11

SIMPLE AntibodyTM platform: powerful engine behind argenx’ pipeline

12

Agenda

• Company overview

• SIMPLE antibodyTM platform

• PD-1

• VISTA

• LAG-3

• Innovative access program

PD-1: highly successful I/O target

Identity human vs mouse: 61% in extracellular domain

• Multiple functional epitopes: nivolumabversus pembrolizumab

• None of the commercialized anti-PD-1 programs are human/mouse cross-reactive; a surrogate anti-mouse PD-1 antibody was needed

• RMPI-14 is most commonly used surrogate anti-PD-1 antibody for mouse syngeneic tumor models

Tan et al. 2017, .Nat Commun.

Generation human – mouse cross-reactive anti-PD-1 mAbs:• Immunization llama with recombinant human PD-1 protein • Phage selection on recombinant murine PD-1

0 1 0 2 0 3 0

0

1 0 0 0

2 0 0 0

3 0 0 0

D a y s P o s t In je c tio n

tum

ou

r v

olu

me

(m

m³) Is o ty p e

R M P I-1 4 Ig G 2 a

R M P I-1 4 Ig G 2 a F c s ile n t

M C 3 8 tu m o r g ro w th

Epitope mapping Nivolumab and Pembrolizumab

14

15

Characterization of argenx anti-PD1 antibody 10F4

Binding to PD-1 and competition with PD-L1 as measured in flow cytometry

0

5 0 0 0 0

1 0 0 0 0 0

1 5 0 0 0 0

2 0 0 0 0 0

B in d in g o n h /m P D -1 t ra n s fe c te d H E K 2 9 3 E

FA

CS

MF

I

1 6 µ g /m l

4 µ g /m l

1 µ g /m l

0 .2 5 µ g /m l

0 µ g /m l

0

5 0

1 0 0

1 5 0

C o m p e t it io n w ith P D -L 1

% c

om

pe

titi

on

1 6 µ g /m l

4 µ g /m l

1 µ g /m l

0 .2 5 µ g /m l

0 µ g /m l

• Binding to transiently PD-1 transfected HEK293 cells• Competition with PD-L1 protein for binding to transiently PD-1 transfected HEK293 cells

Isotype 10F4

hPD1 mPD1 hPD1 mPD1

Isotype 10F4

hPD1 mPD1 hPD1 mPD1

15

Conclusion• 10F4 binds human and mouse PD-1 • 10F4 blocks binding of PD-L1 to both human and mouse PD-1• The argenx anti-PD-1 mAb 10F4 is a human/mouse cross-reactive neutralizer

Anti-PD-1 antibody 10F4 restores T-cell function in human and mouse mixed lymphocyte reaction (MLR)

16

IFNγ release used as read-out for mixed lymphocyte reaction

Is o typ e c tr l 1 0 F 4

0

2 0 0

4 0 0

6 0 0

M o u s e M L R

A b tre a tm e n t (1 0 µ g /m l)

IFN

(p

g/m

l)

Is o typ e c tr l 1 0 F 4

0

5 0 0

1 0 0 0

1 5 0 0

H u m a n M L R

A b tre a tm e n t (1 0 µ g /m l)

IFN

(p

g/m

l)

Conclusion• Anti-PD-1 mAb 10F4 restores T-cell activation in both human and mouse MLR, suggesting

alleviation of PD-1 mediated inhibition

• APC: moDCs• T-cell: CD4+ T-cells

• APC: BMDCs from Balb/C • T-cell: CD4+ T-cells from C57Bl/6 spleen

17

Dahan et al, 2015

RMP1-14 Fc variants

Efficacy study: MC38 syngeneic tumor modelStrong inhibition of tumor growth with 10F4 treatment

Conclusion• Anti-PD-1 mAb 10F4 and RMPI-14 are equally potent in reducing MC38 tumor growth• Removing effector functions dramatically improves the inhibition of tumor growth, in line with

published data from Dahan et al.

0 1 0 2 0 3 0

0

1 0 0 0

2 0 0 0

3 0 0 0

4 0 0 0

d a y s a fte r tre a tm e n t o n s e t

tum

ou

r v

olu

me

(m

m³)

Is o ty p e

1 0 F 4 m Ig G 2 a

1 0 F 4 m Ig G 2 a F c s ile n t

M e a n tu m o r v o lu m e M C 3 8 + S E M

* * *R M P I-1 4 F c s ile n t

Dahan et al. 2015, Cancer Cell

C57BL/6 mice with MC38 tumor, dosed 2x per week with 10 mg/kg

17

Iso

typ

e

10F

4 W

T

10F

4 F

cD

0

2 0

4 0

6 0

8 0

%C

D8

+ c

ell

s

C D 8 c e lls

*

Iso

typ

e

10F

4 W

T

10F

4 F

cD

0 .0

0 .1

0 .2

0 .3

0 .4

% G

ra

nz

ym

eB

+C

D8

+

C y to to x ic T ly m p h o c y te s

*

*

Iso

typ

e

10F

4 W

T

10F

4 F

cD

0

2

4

6

P ro life ra t in g C D 8 c e lls

%K

i67

CD

8+

Efficacy study: MoA analysis

Conclusion• Higher % of total intratumoral CD8+ T-cells with effector-dead anti-PD1 mAb 10F4• Increased % of proliferating and cytotoxic CD8+ T-cells with effector-dead anti-PD-1 mAb 10F4• Similar observation by Dahan et al, 2015 Cancer Cell• 10F4 is a novel in vitro and in vivo relevant human/mouse cross-reactive checkpoint inhibitor

Flow cytometry analysis of tumor-infiltrating lymphocytes from MC38 model

Establishment of increased active CD8+ T-cell population in MC38 tumors

18

Agenda

• Company overview

• SIMPLE antibodyTM platform

• PD-1

• VISTA

• LAG-3

• Innovative access program

VISTA: target info

• Related to B7 family, in particular PD-L1

• Alternative names: Dies1, Gi24, C10orf54, PD-1H, B7-H5

• Single IgV domain, small intracellular domain

• Functions as both receptor and ligand?

• Binding partner poorly defined (VSIG8, VSIG3?)

• VISTA suppresses T-cell function

• High VISTA expression in MDSCs and TregsVISTA blockade to restore anti-tumor response

• High VISTA expression in AML cells tumortarget (e.g. ADC molecule)

Identity human vs mouse: 69% in extracellular domain

Structure of human VISTA ECD

20

VISTA expression in myeloid and lymphoid cells

Lines et al. 2014, Cancer Res.

Anti-mVISTA antibody 13F3 is mostly used surrogate antibody for syngeneic tumor models

• CT26 (colon carcinoma) tumor model in BALB/c mice• Treatment every 2-3 days with 300 µg anti-VISTA, anti-PD-L1 or combo

Liu et al. 2015 PNAS

Le Mercier et al. 2014 Cancer Res.

• B16-OVA tumor model in C57BL/6 mice• Treatment every 2 days with 300 µg anti-VISTA 13F3

More IFN-γproducing cells in tumor-draining lymph node

21

• Llama immunization with VISTA protein• Phage display selections on recombinant hVISTA yielded a panel of mAbs• Antibody specificity was tested in ELISA

Identification and characterization of argenx anti-VISTA mAb 11C5

h u m a n V IS T A

0 .0 1 0 .1 1 1 0 1 0 0

0

1

2

3

4

6 C 1 1

6 F 3

6 C 4

6 C 5

7 A 1 2

1 1 C 5

7 H 10

a n ti-m V IS T A

m A b (µ g /m l)

OD

45

0

m o u s e V IS T A

0 .0 0 1 0 .0 1 0 .1 1 1 0

0

1

2

3

4

6 C 1 1

6 F 3

6 C 4

6 C 5

7 A 1 2

1 1 C 5

7 H 10

a n ti-m V IS T A

m A b (µ g /m l)O

D4

50

• One unique antibody (11C5) shows binding to both human and mouse VISTA in ELISA

22

Light chain shuffling of 11C5 greatly improves the human-mouse cross-reactivity

0 .0 0 0 1 0 .0 1 1 1 0 0

0

1

2

3

4

C o n c e n tra tio n (g /m l)

OD

45

0 n

m

1 1 C 5 h V IS T A

2 4 B 1 h V IS T A

1 1 C 5 m V IS T A

2 4 B 1 m V IS T A

R e c o m b in a n t V IS T A b in d in g E L IS A

11C

5

24B

1

11C

5

24B

1

0

2 0 0 0 0

4 0 0 0 0

6 0 0 0 0

8 0 0 0 0

1 0 0 0 0 0

B in d in g to H E K -V IS T A

C o n c e n tra tio n (g /m l)M

FI

(PE

)

h V IS T A m V IS T A

• 11C5 heavy chain re-introduced into parental light chain library• Stringent phage display selections to find improved VH-VL pair

24B1 is one of the light chain variants of 11C5• Binding to human and mouse VISTA tested on recombinant protein and cells

• New light chains were identified with improved affinity to VISTA• Light chain shuffled antibodies display a clear human/mouse cross-reactivity on cells• Binding was confirmed on monocytes

23

Antibody 300µg : 3 injections per week I.P.

D1D0 Tumor growth measured by caliper D27

Tumor: s.c.

Anti-VISTA mAb 24B1 shows anti-tumor activity in B16-OVA model

3x105 B16-OVA in C57BL6/j female

Study design

B 1 6 O V A

0 1 0 2 0

0

5 0 0

1 0 0 0

1 5 0 0

2 0 0 0

2 5 0 0

Is o ty p e c o n tro l

a n ti-V IS T A 2 4 B 1

a n ti-P D -1

a n ti-V IS T A + a n ti-P D -1

d a y (s )

tu

mo

r v

olu

me

(m

m3

)

* * * *

p < 0 .0 0 0 1

* *

s u r v iv a l c u r v e

d a y (s )

Pe

rc

en

t s

urv

iva

l

0 2 0 4 0 6 0 8 0

0

5 0

1 0 0 Is o ty p e c o n tro l

a n ti-V IS T A 2 4 B 1

a n ti-P D -1

a n ti-V IS T A + a n ti-P D -1

T re a tm e n t

• Anti-VISTA 24B1 is effective in B16-OVA tumors in combo with anti-PD-124

Individual B16-OVA tumor growth curves

A n ti-V IS T A v s is o ty p e

0 2 0 4 0 6 0

0

5 0 0

1 0 0 0

1 5 0 0

2 0 0 0

2 5 0 0

Is o ty p e c o n tro l

a n ti-V IS T A 2 4 B 1

d a y (s )

tum

or v

olu

me

(m

m3

)

A n ti-P D -1 v s is o ty p e

0 2 0 4 0 6 0

0

5 0 0

1 0 0 0

1 5 0 0

2 0 0 0

2 5 0 0

Is o ty p e c o n tro l

a n ti-P D -1

d a y (s )

tum

or v

olu

me

(m

m3

)

A n ti-V IS T A v s a n ti-P D -1

0 2 0 4 0 6 0

0

5 0 0

1 0 0 0

1 5 0 0

2 0 0 0

2 5 0 0

Is o ty p e c o n tro l

a n ti-V IS T A + a n ti-P D -1

d a y (s )

tum

or v

olu

me

(m

m3

)

• Early immune escape is seen in anti-PD-1 treatment group• No early immune escape seen in combo treatment group

-> anti-VISTA can overcome non-responsiveness to PD-1 treatment

25

Agenda

• Company overview

• SIMPLE antibodyTM platform

• PD-1

• VISTA

• LAG-3

• Innovative access program

LAG-3: panel of cross-reactive binders

Identity human vs mouse: 69% in extracellular domain

1 0 -1 1 0 0 1 0 1 1 0 2 1 0 3 1 0 4 1 0 5

0

1

2

3

4

m L A G -3 b in d in g E L IS A

A n ti-L A G -3 (n g /m l)

OD

45

0

1 0 B 5

1 0G 4

1 0 C 8

1 0 E 1 1

1 0 G 11

1 0 E 9

1 0 C 7

4H 51 0 -1 1 0 0 1 0 1 1 0 2 1 0 3 1 0 4 1 0 5

0

1

2

3

4

h L A G -3 b in d in g E L IS A

A n ti-L A G -3 (n g /m l)

OD

45

0

1 0 B 5

1 0G 4

1 0 C 8

1 0 E 1 1

1 0 G 11

1 0 E 9

1 0 C 7

2 5 F 7

• Llama immunization with human LAG-3-Fc protein• ScFv library format for selections on recombinant LAG-3-Fc• Screening for h/m cross-reactive binding

• We identified a collection of h/m cross-reactive anti-LAG-3 antibodies

27

Blocking LAG-3 function: hitting a functional epitope with potential for improvement

28

0 .0 1 0 .1 1 1 0 1 0 0

0

1 0 0 0 0

2 0 0 0 0

3 0 0 0 0

4 0 0 0 0

5 0 0 0 0

C o n c e n tra tio n a n t i-L A G -3 m A b (u g /m l)

RL

U

2 5 F 7

1 0 B 5

1 0 G 11

1 0 C 7

1 0G 4

4H 5

Epitope B

Epitope C

Epitope A

• One group of cross-reactive LAG-3 blocking antibodies identified• Expected to improve potency further by:

• Chain shuffling (cfr. VISTA)• Reformatting to full IgG

• Antibodies (ScFv-Fc) were tested in cell based LAG-3 blocking assay (Promega)LAG-3 inhibition results in TCR signalling and induced luminescence

• Anti-LAG-3 25F7 (Medarex) was used as positive control

Anti-mouse LAG-3

….and also beyond I/O targets !

29

In h ib it io n o f p ro life ra tio n :h u m a n IL -2 4

1 1 0 1 0 0 1 0 0 0 1 0 0 0 0

0 .0

0 .5

1 .0

1 .5

2 .0

2 .5

1 C 1 1

1 C 8

1 C 7

1 D 9

m A b (n g /m l)

OD

45

0 n

m

In h ib it io n o f p ro life ra tio n :m o u s e IL -2 4

1 1 0 1 0 0 1 0 0 0 1 0 0 0 0

0 .0

0 .2

0 .4

0 .6

0 .8

1 C 1 1

1 C 8

1 C 7

1 D 9

m A b (n g /m l)

OD

45

0 n

m

• IL-24 antibody 1C11 cross-reactive to human and mouse IL-24 (69% identity)• Functional test for inhibition of IL-24 –dependent cell proliferation

• Antibody 1C11 is a unique, very potent inhibitor of both human and mouse IL-24 signalling• 1C11 was identified in primary screenings • Room for further improvements using the SIMPLE AntibodyTM platform

W T W T IL 2 2 R -/ - IL 2 2 -/ - IL 2 2 -/ -

0

1 0

2 0

3 0

Ea

r t

hic

kn

es

s (

mm

*1

0-2

)

P P D

m A b is o 1 C 1 1

m ic e

In vivo: inhibition of PPD-induced ear swelling

In vitro: inhibition of IL-24 dependent cell proliferation

Conclusions

Summarizing:

- By using llama as third species we generated panels of human/mouse cross-reactive SIMPLE AntibodiesTM against multiple immune checkpoint targets

- In vitro and/or in vivo studies confirmed unique cross-reactive functionality of these antibodies

- Having human-cyno-mouse cross-reactive antibodies significantly de-risks the therapeutic lead candidate

30

31

Establishing close collaborationswith renowned research groups

Leveraging the power of our unique antibody technology platform

Unlocking novel targets,elucidating target biology

Creating first-in-class antibodieswith therapeutic product potential

Set-up a win-win collaboration: Rapid PoC in disease models; Scientific publications, new IP; Development candidates

Innovative Access Program (IAP): Uniting world-class mAbexpertise with novel targets

WANT TO DISCUSS COLLABORATIONOPPORTUNITIES? CONTACT US.iap@argenx.comwww.argenx.com

Collaboration with UCL/ DeDuve Institute

Patented inventions on GARP & ARGX-115

Pioneering work in immuno-Oncology

Patent published

PoC established, option exercised

Science Translational Medicine publication

AbbVie deal: $40m upfront / early MS

Financial return to UCL/ DeDuve Institute

ARGX-115: IAP success story

32

Establishing close collaborationswith renowned research groups

Leveraging the power of our unique antibody technology platform

Unlocking novel targets,elucidating target biology

Creating first-in-class antibodieswith therapeutic product potential

Set-up a win-win collaboration: Rapid PoC in disease models; Scientific publications, new IP; Development candidates

Innovative Access Program (IAP): Uniting world-class mAbexpertise with novel targets

WANT TO DISCUSS COLLABORATIONOPPORTUNITIES? CONTACT US.iap@argenx.comwww.argenx.com

Many thanks to:

33

argenx BVBABas van der WoningGitte de BoeckLiesbeth HeyndrickxChristel DubuissonKathleen MoensJulie GhyselinckNico OngenaeValérie HanssensChristophe BlanchetotHans de HaardMichael Saunders

FairJourney BiologicsMaria PajueloIldikó TóthDaniela Teixeira Diana RamosJoana Gomes

VIB (Flamish Biotechnology Institute)Eline Haspeslagh

Radboud University NijmegenMichael ValenteCarl Figdor

Crown BioFei ChenQiu Tan

Thank you

WANT TO DISCUSS COLLABORATIONOPPORTUNITIES? CONTACT US.iap@argenx.comwww.argenx.com